Cell Matrix Inc. (Acquired By CancerVax)
1929 Zonal Avenue
Los Angeles
California
90033
U.S.A.
Phone:
323-343-8500
Fax:
323-343-8989
|
Cell Matrix Inc. (CMI) is rapidly building a leadership position in the discovery and development of inhibitors of angiogenesis. The company's lead products have been shown to be potent and highly selective inhibitors of angiogenesis, the process by which new blood vessels are formed to fuel the growth and metastasis of tumors.
CMI was founded in fall of 1999 by highly regarded scientists in the field of oncology and angiogenesis research to commercialize the recent discoveries of Peter C. Brooks, PhD as to the role of "cryptic" sites on extracellular matrix (ECM) proteins in the angiogenesis cascade. Dr. Brooks has shown that during tumor stimulated ECM remodeling, collagen denaturation exposes essential regulatory sites, which directly contribute to endothelial cell migration and new blood vessel growth.
CMI is developing monoclonal antibodies that target binding sites that are selectively exposed as a result of ECM remodeling. These antibodies have been shown to have therapeutic potential based on preclinical study results including:
- Inhibition of new blood vessel growth
- Inhibition of endothelial cell adhesion and migration
- Selective staining of tumor associated blood vessels
- Detection of elevated levels of denatured collagens in cancer patient serum
- Inhibition of tumor growth
- Inhibition of metastasis
CMI accomplishments in the identification of novel targets for angiogenesis regulation, discovery of molecules which block these targets, and the humanized antibody product development program have positioned CMI as a leader in drug discovery and development based on novel mechanisms of angiogenesis regulation.
Last Updated 7-10-01
Email:
kcarner@cell-matrix.com
Ownership:
Private
Web Site:
Cell Matrix Inc. (Acquired By CancerVax)
Employees:
12
Symbol:
|